Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06180928
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-26
First Post:
2023-12-03
Brief Title:
Short Term Outcome of Metabolic Associated Fatty Liver Disease MAFLD in Patients Undergoing Bariatric Surgery
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Short Term Outcome of Metabolic Associated Fatty Liver Disease MAFLD in Patients Undergoing Bariatric Surgery
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Obesity has become one of the most critical public health problems in economically developed and developing countries in the world
Bariatric surgery is an option for obese individuals who fail to achieve suitable weight loss with lifestyle changes and pharmacological methods Bariatric surgery can help obese individuals achieve recommended weight reduction and thus improve the course of MAFLD The additional benefits of bariatric surgery include resolution or amelioration of hypertension hyperlipidemia and type 2 diabetes and reduction of cardiovascular risk and mortality
The relation between rate of weight loss after bariatric surgeries and the course of the MAFLD not well studied befor So we are aiming to assess the outcome of MAFLD TSH in patients undergoing Barietric surgeries and if there is significant correlation of steatosis and rate of weight loss among those patients
Bariatric surgery is an option for obese individuals who fail to achieve suitable weight loss with lifestyle changes and pharmacological methods Bariatric surgery can help obese individuals achieve recommended weight reduction and thus improve the course of MAFLD The additional benefits of bariatric surgery include resolution or amelioration of hypertension hyperlipidemia and type 2 diabetes and reduction of cardiovascular risk and mortality
The relation between rate of weight loss after bariatric surgeries and the course of the MAFLD not well studied befor So we are aiming to assess the outcome of MAFLD TSH in patients undergoing Barietric surgeries and if there is significant correlation of steatosis and rate of weight loss among those patients
Detailed Description:
Obesity has become one of the most critical public health problems in economically developed and developing countries in the world It causes metabolic disorders that increase the risk of mortality and morbidity in adulthood Furthermore obesity contributes significantly to the pathogenesis of diabetes mellitus cardiovascular disease hyperlipidemia obstructive sleep apnea and hypertension pathogenesis
Non-alcoholic fatty liver disease NAFLD is defined by macrovesicular steatosis in 5 hepatocytes in the absence of a secondary cause such as alcohol or drugs It includes a spectrum of diseases from non-alcoholic fatty liver NAFL through to non-alcoholic steatohepatitis NASH fibrosis and cirrhosis The worldwide prevalence of NAFLD is about 25 ranging from 13 in Africa to 23 in Europe and 32 in the Middle East Non-alcoholic fatty liver disease NAFLD is a recognized complication of obesity
Recently it has been proposed to change the name of non-alcoholic fatty liver disease NAFLD to Metabolic Associated Fatty Liver Disease MAFLD to better reflect the pathophysiology of the disease MAFLD may better reflect the pathophysiology of this disorder and provides a broad definition for this heterogeneous disorder The criteria are based on the evidence of hepatic steatosis plus any of the following three conditions overweight obesity presence of type 2 diabetes mellitus T2DM or evidence of metabolic dysregulation
Obesity is associated with high TSH levels Clinical studies have shown a positive correlation between obesity and plasma TSH levels Furthermore weight loss in these patients is associated with changes in serum TSH and thyroid hormone levels
Bariatric surgery is an option for obese individuals who fail to achieve suitable weight loss with lifestyle changes and pharmacological methods Bariatric surgery can help obese individuals achieve recommended weight reduction and thus improve the course of MAFLD The additional benefits of bariatric surgery include resolution or amelioration of hypertension hyperlipidemia and type 2 diabetes and reduction of cardiovascular risk and mortality
Also The decrease in adipose tissue after bariatric surgery causes changes in plasma fT3 fT4 and TSH levels obese patients had a decreased thyroid hormone gene expression especially TSH receptor in subcutaneous and visceral adipose tissue
The relation between rate of weight loss after bariatric surgeries and the course of the MAFLD not well studied befor So we are aiming to assess the outcome of MAFLD TSH in egyption patients undergoing Barietric surgeries and if there is significant correlation of steatosis and rate of weight loss among those patients
Non-alcoholic fatty liver disease NAFLD is defined by macrovesicular steatosis in 5 hepatocytes in the absence of a secondary cause such as alcohol or drugs It includes a spectrum of diseases from non-alcoholic fatty liver NAFL through to non-alcoholic steatohepatitis NASH fibrosis and cirrhosis The worldwide prevalence of NAFLD is about 25 ranging from 13 in Africa to 23 in Europe and 32 in the Middle East Non-alcoholic fatty liver disease NAFLD is a recognized complication of obesity
Recently it has been proposed to change the name of non-alcoholic fatty liver disease NAFLD to Metabolic Associated Fatty Liver Disease MAFLD to better reflect the pathophysiology of the disease MAFLD may better reflect the pathophysiology of this disorder and provides a broad definition for this heterogeneous disorder The criteria are based on the evidence of hepatic steatosis plus any of the following three conditions overweight obesity presence of type 2 diabetes mellitus T2DM or evidence of metabolic dysregulation
Obesity is associated with high TSH levels Clinical studies have shown a positive correlation between obesity and plasma TSH levels Furthermore weight loss in these patients is associated with changes in serum TSH and thyroid hormone levels
Bariatric surgery is an option for obese individuals who fail to achieve suitable weight loss with lifestyle changes and pharmacological methods Bariatric surgery can help obese individuals achieve recommended weight reduction and thus improve the course of MAFLD The additional benefits of bariatric surgery include resolution or amelioration of hypertension hyperlipidemia and type 2 diabetes and reduction of cardiovascular risk and mortality
Also The decrease in adipose tissue after bariatric surgery causes changes in plasma fT3 fT4 and TSH levels obese patients had a decreased thyroid hormone gene expression especially TSH receptor in subcutaneous and visceral adipose tissue
The relation between rate of weight loss after bariatric surgeries and the course of the MAFLD not well studied befor So we are aiming to assess the outcome of MAFLD TSH in egyption patients undergoing Barietric surgeries and if there is significant correlation of steatosis and rate of weight loss among those patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None